Expression of GATA3 in MDA-MB-231 Triple-negative Breast Cancer Cells Induces a Growth Inhibitory Response to TGFβ

Isabel M. Chu¹a, Wei-Chu Lai, Olga Aprelikova, Lara H. El Touny, Hosein Kourosh-Mehr²b, Jeffrey E. Green*

Introduction

GATA3 is a transcription factor belonging to the GATA family of Zn-finger family members. GATA3 has been mainly implicated in cell fate decisions during development and differentiation of the hematopoietic cell lineages [1] and more recently, of mammary gland development [2,3]. GATA3 is critical for luminal differentiation during mammary gland development and is expressed only in the ducts and terminal end buds (TEB) of luminal cells [2]. Loss of GATA3 expression has been associated with a worse prognosis in breast cancer patients [4]. Our lab and others have shown that overexpression of GATA3 in the metastatic MDA-MB-231 (MB-231) basal triple-negative breast cancer cell line reduces tumorigenesis and metastasis [5–7]. Here we show that GATA3 promotes a mesenchymal-to-epithelial transition (MET) in MB-231 cells, reduces TGFβ dependent epithelial-to-mesenchymal transition (EMT) response and most importantly, results in a TGFβ cytostatic effect in the metastatic cell line, MB-231.

EMT is a reversible process that involves loss of an epithelial phenotype and a concomitant acquisition of a mesenchymal phenotype. EMT is present during embryogenesis and tissue development and is often recapitulated during tumor progression, resulting in increased invasiveness and a more aggressive phenotype [8,9]. EMT is characterized by loss of apical-basolateral cell polarity, actin reorganization and increased extracellular matrix protein deposition resulting in increased migration and invasion [10]. One of the hallmarks of EMT is the downregulation or loss of E-cadherin [9]. E-cadherin is transcriptionally repressed by ZEB1, ZEB2, SNAI1, SNAI2, Twist1, Twist2 and E12/E47 [11]. E-cadherin loss promotes metastasis through induction of EMT, invasiveness and anoikis resistance [12]. Cancer cells undergo localized EMT at the invasive front of the tumor and extracellular cues, including activation of TGFβ and Wnt at the tumor front, and expression of EMT markers prime cells for metastatic dissemination [13].

The role of the pleiotropic cytokine transforming growth factor β1 (TGFβ1), a potent inducer of EMT and tumor progression in many types of cancers including breast cancer, has been well documented [14]. TGFβ1 belongs to the TGFβ superfamily and has been implicated in regulating proliferation, differentiation,
adhesion, apoptosis, migration, homeostasis and tissue repair [15]. Binding of TGFß to the TGFß type II receptor (TGFßRII) leads to receptor activation, heterodimerization and phosphorylation of the TGFß type I receptor (TGFßRI) at a glycine-serine rich domain. The TGFßRI can then recruit, phosphorylate and activate the receptor-regulated Smads - Smad2 and Smad3 (R-Smads) - whereby phosphorylated Smad2/3 accumulate in the nucleus and bind to the common partner Smad 4 (co-Smad). These Smad complexes regulate transcriptional activators or repressors of gene expression.

Although TGFß response is growth inhibitory in most epithelial cells, advanced tumors of epithelial origin often show oncogenic responses to TGFß [16]. During mammary gland development, TGFß plays a mostly growth inhibitory role in mammary epithelial cells and is involved in branching morphogenesis, lactation and involution [17]. In breast cancer, TGFß acts as a tumor suppressor during early stages of cancer development. In contrast, TGFß acts as a tumor promoter at later stages of tumorigenesis and promotes metastatic spread [16,18].

This paradoxical role of TGFß in breast cancer has been widely studied in different models of breast cancer. Tang and colleagues investigated TGFß response using a panel of MCF10A-derived cell lines that included the weakly tumorigenic MCF10Ca1a line (designated MIII in this manuscript) which retained tumor suppressor responses to TGFß and the metastatic, highly tumorigenic MCF10Ca1a.c11 line in which tumor suppressor responses to TGFß were lost and pro-metastatic responses were unmasked [19]. In MMTV-Neu-induced mammary tumorigenesis, activation of the TGFß signaling pathway through the use of an activated TGFßRII resulted in increased lung metastasis, but increased the latency of primary tumor formation, whereas a dominant-negative TGFßRI resulted in the converse effects [20]. Although the existing models to investigate TGFß have shed some light into the mechanisms involved in pro- or anti-oncogenic vs. tumor suppressive functions, there are some limitations to the established models for studying the effects of TGFßExisting cell lines used to investigate the paradoxical role of TGFß are either derived from different cellular origins or have been manipulated through passage in mice where the cells may undergo additional modifications.

Here we present a novel isogenic cell model system in which only one gene, GATA3, was ectopically expressed in MB-231 cells that dramatically alters the cellular response to TGFßUsing this model system, we have shown that GATA3 alone is sufficient to re-sensitize this cell line to the cytostatic effects of TGFß and provide a putative mechanism for this change in response to TGFß through alterations in the expression of cell cycle regulators and genes that regulate EMT. This model system provides new insights into how a differentiation transcription factor, GATA3, is involved in regulating the TGFß response.

Materials and Methods

Cell lines, transfection and lentivirus infection

MB-231 cells were obtained from American Type Culture Collection (ATCC) and maintained in DMEM/high glucose media (Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS) (Life Technologies), penicillin/streptomycin (Life Technologies) and sodium pyruvate (Life Technologies). For TGFß1 treatment, cells were grown in DMEM/high glucose supplemented with serum replacement (SR, Sigma, St. Louis, MO) for 24 hrs prior to TGFß1 stimulation. Cells were treated with 2 ng/ml of TGFß. MB-231 cells stably expressing green fluorescent protein (GFP) or the GATA3 transcription factor and GFP were made as previously described [5]. MCF10Ca1a [21] cells were kindly provided by Lalive Wakefield, NCI.

Construction of E-cadherin (CDH11) reporter construct

The E-cadherin reporter construct was generated using the 4 kb promoter fragment upstream of the E-cadherin first exon that was PCR amplified from a BAC genomic DNA template (human BAC 534M1) using the following primers: Forward GAGTTACCT-GATACAGAGAAAA CAGAGGGC and Reverse GA-GACGCCGTTGCGTGGCAGGGGGAGCGCCGAG. The promoter fragment was then cloned into the KPN1 and Mlu1 sites of the PG13-luciferase reporter plasmid (Promega, Madison, WI).

Luciferase activity

For luciferase activity, 231-Empty and 231-GATA3 cells were seeded on 24 well plates, transfected for 24 hrs with E-cadherin reporter construct and renilla luciferase, samples were collected and luciferase activity measured using Wallac Victor™ (Perkin Elmer, Waltham, MA). Samples were normalized to renilla activity.

Methylation-specific PCR

Cells were treated with vehicle or 5-Aza-2'-deoxycytidine (5-AZA, Sigma) for 4 days prior to DNA isolation. DNA was isolated from stably transduced 231-Empty and 231-GATA3 cells using the DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol; DNA was sullenfated using the EZ DNA Methylation™ Kit (ZYMO Research, Irvine, CA). Methylation-specific PCR was performed with the following primer sets: 5'-GGTGAATT TTTAGTTAATTAGCGGTAC -3' and 5'-GATAACTAAACGAAAACCGCCG-3' for methylated CDH1; 5'-GGTAGGAATT TTTAGTTAATTAGCGGTAC -3' and 5'-ACCGATAACTAAGC AAAAAACACCA-3' for unmethylated CDH1 (211 bp) [22]. Bisulfite-treated DNA was PCR-amplified with annealing temperatures of 57°C for both methylated and unmethylated CDH1 DNA.

Quantitative reverse transcription PCR (Q-RT-PCR)

cDNA was synthesized from 1 μg of total RNA using the Superscript III kit (Life Technologies). Q-RT-PCR was performed using IQ SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA) and an iCycler Thermal Cycler (Bio-Rad Laboratories). The quantity of mRNA was normalized to the housekeeping gene cyclophilin B.

Immunoblotting and antibodies

Cells were lysed in ice-cold RIPA buffer for Western blot analyses as described previously [5]. GATA3 (558686) and p21 (sc-397) antibodies were purchased from Santa Cruz (Santa Cruz, CA); Twist (ab50857), β-catenin (ab32572), Smad3 (ab28379) were from Abcam (Cambridge, MA); Smad1 (3839), Phospho-Smad2 (3108), Phospho-Akt (Ser473, 9271), Akt (9272), p44/42 MAP Kinase (9102), Phospho-p44/42 MAPK (9106), E-cadherin (4065), Smad2 (3105), Phospho-Smad1/5/8 (9511) and Slug (9585) were purchased from Cell Signaling Technology (Danvers, MA); Phospho-Smad3 (1880-1) was purchased from Epitomics (Burlingame, CA); Smad1 (385400) was purchased from Life Technologies.

Knockdown of GATA3 or BMP5

3×10⁵ cells in 6-well plates were transfected with 60 nM siRNA for GATA3 (Dharmacon, J-003781-07 and J-003781-09) or
siRNA for BMP5 (Qiagen, S100129094 and S100129100) or non-targeting control using Oligofectamine Reagent (Invitrogen) according to the manufacturer’s protocol. To knock down GATA3 in 231-GATA3 cells, transfection with siRNA was performed on two consecutive days. On the third day, cells were plated in serum-free media followed by TGFβ treatment as above. After 24 hours cells were labeled with BrdU and subjected to flow cytometry analysis.

**Microarray data processing**

Total RNA was isolated using Trizol® according to the manufacturer’s protocol (Life Technologies). RNA quality was checked using an Agilent Bioanalyzer (Agilent, Santa Clara, CA, USA). All samples used for microarray analysis had a high quality score (RIN > 9). RNA (1 μg) was reverse transcribed with a T7-oligo(T) primer and biotin labeled using the Affymetrix One Cycle Target Labeling kit (Affymetrix, Santa Clara, CA) following the manufacturer’s protocol. For 231-Empty vs. 231-GATA3 cells, samples were analyzed using BRB-ArrayTools developed by Richard Simon and the BRB-ArrayTools Development Team (http://linus.nci.nih.gov/BRB-ArrayTools.html) as previously described [5]. For 231-Empty or 231-GATA3 cells in serum replacement (SR) −/+ transforming growth factor beta-1 (TGFβ1), four replicates of each group were prepared, labeled, and hybridized to Affymetrix Human Gene 1.0 ST array GeneChips and scanned on an Affymetrix GeneChip Scanner 3000. Data were collected using Affymetrix GCOS software and processed into log 2 base gene expression measures using the RMA algorithm and quantile normalization using PARTEK software (PARTEK, St. Louis, MO). Network analysis was done using Ingenuity Pathway Analysis (Redwood City, CA).

**Flow cytometry**

Cell cycle profiles were assayed by 5-bromo-2-deoxyuridine (BrdU) pulse labeling and flow cytometric analysis was performed as previously described [5] using FACScalibur (Becton Dickinson, Franklin Lakes, NJ).

**Statistical analyses**

Q-RT-PCR mean differences were tested with an unpaired Student’s t test. Statistical significance was depicted in the figures as *p < 0.05, **p < 0.01 and ***p < 0.001. All in vitro experiments were repeated at least 3 times. Differentially expressed genes between 231-Empty and 231-GATA3 cells grown in full serum were identified with univariate unpaired Student’s t-test and p-value threshold of 0.001, using the BRB-ArrayTools statistical software. Differentially expressed genes between 231-Empty and 231-GATA3 cells grown in SR −/+ TGFβ were identified using PARTEK software.

**Results**

**GATA3 promotes expression of epithelial markers and loss of mesenchymal markers in MB-231 cells**

The derivation of 231-Empty and 231-GATA3 cells has been previously described [3]. Our lab and others have demonstrated that the overexpression of GATA3 in MB-231 cells results in morphological changes from a spindloid phenotype to a cuboidal, epithelial appearance in 2D culture, a more organized structure in 3D culture, and a significant reduction in tumorigenesis and metastasis when implanted as xenografts [5–7]. In addition to the morphological and biological changes induced by GATA3 in MB-231 cells that we described previously [5], our analyses of microarray data comparing 231-Empty cells with 231-GATA3 cells demonstrated a significant reduction in gene expression associated with EMT and an increase in expression of genes associated with MET. Q-RT-PCR analysis confirmed an increase in expression of Tetranspin 13 (TSPAN13), Occludin (OCLN), Zona occludens-1 (ZO1), Claudin 3 (CLDN3) and Claudin 4 (CLDN4) (Figure 1A), which are genes associated with an epithelial or less aggressive phenotype. In contrast, the expression of genes associated with a mesenchymal phenotype were reduced including Cadherin-11 (CDH11), Snail1 (SNAI1), Slug (SNAI2), Twist (TWIST1), Zinc finger E-box-binding homeobox 1 (ZEB1), Vimentin (VIM), Versican (VCAN), Fascin homolog 1 (FSCN1), C-X-C chemokine receptor type 4 (CXCR4) and Fibronectin 1 (FN1) (Figure 1B).

Loss of E-cadherin expression is considered a hallmark of EMT [9]. MB-231 cells lack E-cadherin expression and exhibit a mesenchymal phenotype [23]. Immunofluorescence for E-cadherin and GATA3 protein revealed expression of E-cadherin in the cytoplasmic membrane only in 231-GATA3 cells, but no detectable expression in control 231-Empty cells (Figure 1C). In epithelial cells, β-catenin is co-localized with E-cadherin on the cellular membrane. Immunofluorescence staining for β-catenin revealed homogenous diffuse staining in 231-Empty cells while 231-GATA3 cells showed relocalization of β-catenin to the cellular membrane consistent with E-cadherin expression and localization (Figure 1C). Furthermore, western blot analysis also revealed reduction of β-catenin in 231-GATA3 cells compared to 231-Empty cells (Figure 1D). We generated a luciferase reporter construct containing the 4 kb 5’ genomic promoter region of E-cadherin and observed a 6-fold increase in luciferase activity when this construct was transfected into 231-GATA3 cells compared to 231-Empty cells (p < 0.05, Figure 1E) suggesting that GATA3 can upregulate E-cadherin expression at the transcriptional level.

E-cadherin has previously been shown to be regulated by methylation in MB-231 cells [23]. Therefore, we investigated the methylation status of E-cadherin in 231-GATA3 and 231-Empty cells. By Methylation Specific PCR (MSP), we observed a reduction of methylated DNA at the E-cadherin promoter in 231-GATA3 cells compared to 231-Empty cells, whereas unmethylated DNA was reduced in 231-Empty vs. 231-GATA3 cells (Figure 1F). These changes in promoter methylation status correspond to the total E-cadherin protein levels as determined by western blot (Figure 1F). 231-GATA3 cells re-expressed E-cadherin protein, whereas E-cadherin protein was undetectable in 231-Empty cells by western blot. Treatment with 5-Aza-2’-deoxycytidine (5-AZA), a demethylating agent, resulted in reduction of methylated DNA at the E-cadherin promoter in 231-GATA3 cells. By Methylation Specific PCR (MSP), we observed a 6-fold increase in E-cadherin protein expression in 231-GATA3 cells compared to 231-Empty cells (Figure 1F). 5-AZA also increased expression of E-cadherin in 231-GATA3 cells. These findings suggest that there are methylated sites in the E-cadherin promoter that are independent of GATA3 expression in addition to the GATA3 dependent methylated sites.

**GATA3 overexpression promotes changes in the TGFβ signaling pathway**

We have previously performed Affymetrix microarray analysis of 231-Empty and 231-GATA3 cells to further discern the putative mechanisms utilized by GATA3 to promote changes in EMT. Probes were selected with a 1.5 fold change in expression and based on a nominal 0.001 level of the univariate test. Of these 872 probes, 832 probes were mapped to 832 probes using Ingenuity Pathway Analysis. Ingenuity network analysis revealed that one of the top networks altered upon GATA3 over-expression in MB-231 cells were genes involved in development and morphology (Figure 2A). This network showed a reduction in
the expression of effectors involved in the TGFβ signaling pathway (SMAD1, 2 and 3) in 231-GATA3 vs. 231-Empty cells (Figure 2A). Western blot analysis confirmed a reduction of several of the TGFβ effectors including Smad1, 2 and 3 in 231-GATA3 compared to 231-Empty cells (Figure 2B).

GATA3 overexpression reduces the transcriptional response to TGFβ and TGFβ-dependent EMT stimulation of MB-231 cells

TGFβ has been shown to stimulate EMT [14]. Since 231-GATA3 cells showed reduced expression of EMT markers suggesting a transition towards an epithelial phenotype, we investigated whether the observed MET phenotypic changes were associated with a reduction in response to TGFβ-signaling. To investigate this, 231-Empty and 231-GATA3 cells were transfected with the TGFβ-dependent CAGA12-luciferase reporter construct, grown in the absence of TGFβ1 for 24 hours under serum replacement (SR) conditions, treated with TGFβ1 for 16 hrs and harvested for luciferase activity measurements. Basal luciferase activity was observed in SR media in both 231-Empty and 231-GATA3 cells. Lower panel: western blot of 231-Empty and 231-GATA3 cells for E-cadherin. Cells were treated with 5-AZA for 4 days prior to lysate collection. Treatment of 231-Empty and 231-GATA3 cells with 5-AZA increased E-cadherin expression.

doi:10.1371/journal.pone.0061125.g001

Figure 1. GATA3 over-expression in MB-231 cells promotes EMT and the re-expression of E-cadherin. (A) Q-RT-PCR demonstrates increased expression of epithelial markers in 231-GATA3 cells compared to 231-Empty cells. We observed increased TSPAN13, OCLN, ZO1, CLDN3 and CLDN4 in 231-GATA3 vs. 231-Empty cells. Samples were normalized to cyclophilin B. (B) Q-RT-PCR showing that the relative expression of mesenchymal and metastatic markers is reduced in 231-GATA3 cells compared to 231-Empty cells. We observed reduced CDH1, SNAI1, SNAI2, TWIST1, ZEB1, VIM, VCAN, FSCN1, CXCR4 and FN1 in 231-GATA3 vs. 231-Empty cells. Samples were normalized to cyclophilin B. (C) Immunofluorescence of 231-Empty and 231-GATA3 cells for GATA3, E-cadherin and β-catenin. GATA3 over-expression in MB-231 results in re-expression of E-cadherin associated with the cell membrane and re-distribution of β-catenin. (D) Western blot showing reduced expression of β-catenin in 231-GATA3 cells compared to 231-Empty cells. β-actin was used as loading control. (E) Luciferase activity showing increased activity of the E-cadherin reporter construct in 231-GATA3 cells vs. 231-Empty cells. (F) top panel: PCR using primers that detect only unmethylated or methylated DNA at the E-cadherin promoter of 231-Empty and 231-GATA3 cells. DNA underwent bisulfate treatment prior to the PCR reaction. 231-GATA3 cells show reduced methylated and increased unmethylated DNA in the E-cadherin promoter region compared to 231-Empty cells. Lower panel: western blot of 231-Empty and 231-GATA3 cells for E-cadherin. Cells were treated with 5-AZA for 4 days prior to lysate collection. Treatment of 231-Empty and 231-GATA3 cells with 5-AZA increased E-cadherin expression.
GATA3 inhibits the TGFβ proliferative response in MB-231 cells

The response of breast cancers to TGFβ has been shown to be contextual depending on the stage of disease. Early stage breast cancers or less invasive breast cancer cells are sensitive to the cytostatic effects of TGFβ compared to their more aggressive counterparts that may acquire growth and proliferative advantages in response to TGFβ [16,19]. Since GATA3 reduces tumorigenesis and metastatic potential of MB-231 cells [5], we investigated the proliferative response of 231-Empty and 231-GATA3 cells to TGFβ. Both 231-Empty and 231-GATA3 cells have similar basal proliferation rates as measured by % S phase in full serum or in SR conditions where TGFβ is absent (Figure 4A). The rate of proliferation for 231-Empty cells was not inhibited upon 24 hr stimulation with TGF-β1 (Figure 4A). However, an inhibitory response to TGFβ1 was observed in 231-GATA3 cells (Figure 4A). Percent S-phase of 231-Empty cells did not show a statistical significant change when cells in SR-conditions were stimulated with TGFβ1 (24% and 27% in S-phase, respectively). However, % S-phase of 231-GATA3 cells grown under SR-conditions was remarkably reduced upon TGFβ1 stimulation (21% vs. 8% in S-phase, respectively, p<0.05). To further demonstrate that this inhibitory effect on proliferation by TGFβ1 is mediated by GATA3, we knocked down GATA3 expression in 231-GATA3 cells (Figure 4B). Treatment with TGFβ1 showed robust suppression of S phase in 231-GATA3 cells transfected with non-targeting control, but knock down of GATA3 with two different siRNAs diminished or completely reversed the suppressive effect on proliferation in response to TGFβ1 (Figure 4B).

GATA3 alters the gene expression profile of MB-231 cells in response to TGFβ1

The expression of GATA3 in MB-231 cells resulted in the cells becoming growth inhibited in response to TGFβ1 compared to 231-Empty cells. In order to identify GATA3-dependent transcriptional changes associated with this change in response to TGFβ1, we performed microarray analysis of 231-Empty and 231-GATA3 cells cultured in SR media and stimulated with TGFβ1 for 24 hrs. Pairwise comparisons using PARTEK analysis software
was performed between the cells cultured under the following conditions: 231-Empty cells SR vs. 231-Empty cells SR + TGFß; 231-GATA3 SR vs. 231-GATA3 SR + TGFß; 231-Empty SR vs. 231-GATA3 SR; and 231-Empty + TGFß vs. 231-GATA3+TGFß. A total of 1252 genes were found to be differentially expressed between these treatment groups (>1.6 fold change at p<0.001). The heatmap of the 1252 genes across the four cell treatment groups using unsupervised hierarchical clustering analysis demonstrated distinctions in gene expression among the four groups (upregulated (red) and downregulated (blue) regions) (Figure 5A). Of the 218 genes upregulated in 231-Empty cells upon TGFß1 treatment, only 112 genes were also upregulated in 231-GATA3 cells (Figure 5B). Furthermore, we observed 62 genes that were only upregulated in 231-GATA3 cells in response to TGFß1. Similarly, of the 181 genes downregulated in response to TGFß1 in 231-Empty cells, only 29 genes were also downregulated in 231-GATA3 cells, whereas 29 genes were downregulated only in 231-GATA3 cells (Figure 5B). Further analysis of the set of genes differentially regulated in 231-GATA3 and 231-Empty cells in response to TGFß1 revealed a cluster that contained genes primarily involved in cell proliferation including PCNA, ORC1, CDC45, CCNE2, MCM2 and 7 (Figure 5A and 5C). Genes in this cluster showed either no change or increased expression in response to TGFß1 in 231-Empty cells, whereas TGFß1 stimulation of 231-GATA3 cells reduced the expression of these genes (Figure 5C). The acquired response of 231-GATA3 cells to the reduced expression of proliferative genes in response to TGFß1 may account for the switch from a proliferative to growth inhibitory response of the 231-GATA3 cells. To further explore the differences in TGFß1 response between 231-Empty vs. 231-GATA3 cells, we performed a network analysis using Ingenuity Pathway Analysis and compared changes in the expression of genes associated with cell cycle functions upon TGFß stimulation in 231-Empty and 231-GATA3 cells (Figure 6). This network analysis demonstrated changes in the expression of genes associated with the cell cycle (green indicates a reduction in gene expression upon TGFß treatment, red indicates increased expression, and the intensity of the color represents the degree of change). Among some of the genes that were only reduced or showed a greater degree of reduction in 231-GATA3 vs. 231-Empty cells were Cyclin A, CDK1 and PCNA. Interestingly, we also observed a greater increase in p21 expression in 231-GATA3 vs. 231-Empty in response to TGFß1. These observed changes in cell cycle effectors likely account for the observed restoration to the cytostatic effects of TGFß1 in 231-GATA3 vs. 231-Empty cells.

Figure 3. GATA3 reduces the TGFß1 transcriptional response in MB-231 cells and abrogates TGFß1 mediated EMT. (A) Luciferase activity of 231-Empty and 231-GATA3 cells using the TGFß response reporter construct CAGA12. 231-GATA3 cells exhibited a reduced TGF-ß1-dependent activation of CAGA12 compared to 231-Empty cells. (B) Western blot analysis of 231-Empty and 231-GATA3 cells showing changes in activation of SMAD signaling in response to TGF-ß1. 231-GATA3 cells treated with TGF-ß1 for 1 hr. showed reduced p-SMAD 3 and p-SMAD 2 levels compared to 231-Empty cells. β-actin was used as loading control. (C) Western blot analysis showing differences in expression of EMT markers at the indicated times. Cells were grown in SR media and treated with TGF-ß1 for 12, 24 or 48 hrs. doi:10.1371/journal.pone.0061125.g003
BMP5 treatment of 231-Empty cells restores TGFβ response

Our microarray analysis of 231-Empty vs. 231-GATA3 cells also revealed that BMP5 was highly upregulated upon GATA3 overexpression. We confirmed by Q-RT-PCR a more than 200-fold increase in BMP5 expression in 231-GATA3 compared to 231-Empty cells. Although BMP2 and BMP4 were also altered upon GATA3 expression, the expression changes were minimal compared to BMP5 (Figure 7A). We observed no detectable levels of BMP7 in 231-Empty or 231-GATA3 cells by Q-RT-PCR (data not shown). The changes in BMP5 expression are associated with the levels of phosphorylated Smad1/5/8. These Smads are phosphorylated upon activation of the BMP pathway and basal phosphorylation of these Smads is higher in 231-GATA3 cells compared to 231-Empty cells (Figure 7B). Upon BMP5 treatment, there were elevated p-Smad1/5/8 levels in 231-GATA3 cells compared to 231-Empty cells even though total Smad1 levels were reduced in 231-GATA3 vs. 231-Empty cells (Figure 7B).

In order to investigate whether the GATA3-induced increase in BMP5 expression may contribute to the cytostatic effects of TGFβ1 on MB-231 cells, we treated 231-Empty cells with either TGFβ1 or BMP5 alone or in combination. Whereas treatment of 231-Empty cells grown under SR-conditions with either TGFB1 or BMP5 alone resulted in no change in % S-phase (19%, 23% and 20% in SR, TGFβ1 and BMP5 alone, respectively), combination treatment of 231-Empty cells with TGFβ1 and BMP5 resulted in reduced % S-phase to 14% (p<0.05) compared to SR-conditions (Figure 7C). Since 231-GATA3 cells express very elevated endogenous levels of BMP5, treatment with BMP5 in combination with TGFβ1 did not change the % S-phase compared with treatment of TGFβ1 alone (Figure 7C). Although combining BMP5 with TGFβ1 resulted in an inhibition of proliferation of 231-Empty cells in response to TGFβ1, knock down of BMP5 in combination of an inhibitory antibody for BMP5 in 231-GATA3 cells did not revert the GATA3 effect on TGFβ1 proliferative response (data not shown). It is possible that this treatment did not sufficiently inactivate the high endogenous levels of BMP5 in these cells or that in 231-GATA3 cells in addition to BMP5, GATA3 is promoting additional changes that results in the switch in TGFβ response.

To further explore the role of GATA3 and BMP5 in TGFβ response without ectopic expression of GATA3, we used the MIII cell line. These cells are a tumorigenic derivative of the breast epithelial cell line MCF10A transformed with the activated H-ras oncogene [24]. Previously it has been shown that treatment with TGFβ1 inhibits growth of MIII cells [25]. Furthermore, we detected a robust expression of GATA3 protein in these cells that was significantly decreased by siRNA targeting of GATA3 (Figure 8A). Similar to the response of 231-GATA3 cells to TGFβ1, treatment of MIII cells with TGFβ1 resulted in inhibition of...
of cell proliferation in MIII cells transfected with control non-targeting siRNA. However, the growth suppressive effect of TGFß was blunted by two siRNAs against GATA3 (Figure 8B). The same cells express low, but detectable levels of BMP5 by quantitative RT-PCR. Knock down of BMP5 in MIII cells also partially diminished the inhibitory effect of TGFbeta on cell proliferation (Figure 8C and D), suggesting that BMP5, in fact, contributes to the inhibitory effect of TGFbeta on the proliferation of MIII cells.

Discussion

The paradoxical effects of TGFß—either inducing or inhibiting proliferation have been extensively studied in several systems. However, the mechanisms that regulate these opposing responses to TGFß remain enigmatic. Early stage breast cancers are responsive to the cytostatic effects of TGFß, in contrast to late stage breast cancers that continue to proliferate in the presence of TGFß and acquire a more invasive phenotype [16]. The development of resistance to the cytostatic effect of TGFß may be a critical step during metastatic progression. In this study, we provide a new model to further investigate the switch in TGFß responsiveness in the well characterized triple-negative breast cancer cell line, MB-231. This cell line has been extensively investigated to ascertain effectors involved in metastasis and to investigate TGFß response [26,27]. Our results demonstrate that ectopic expression of the differentiation transcription factor GATA3 in this well characterized metastatic cell line results in sensitization of the cells to the TGFß cytostatic response and promotion of MET, and propose that the expression of BMP5 contributes to this response. Our previous findings demonstrating that GATA3 expression in MB-231 cells induces a more luminal
Figure 6. Network of genes involved in cell cycle regulation. Network of genes that were differentially expressed between 231-Empty and 231-GATA3 by $>1.5$ fold and $p<0.001$ (Ingenuity Pathway Analysis). Green represents reduced gene expression upon TGFβ1 stimulation compared to untreated cells and red represent increased gene expression compared to untreated cells. Intensity of the color represents the degree of change for (A) 231-Empty cells and (B) 231-GATA3 cells. Many more genes in this network are downregulated by TGFβ1 in 231-GATA3 cells compared to 231-Empty cells.

doi:10.1371/journal.pone.0061125.g006
phenotype [5] and that proliferation of these cells is inhibited by TGFβ are consistent with a previous report that demonstrated that proliferation of these cells is inhibited by TGFβ stimulation alone was not sufficient to promote EMT. Co-administration of ionizing radiation with TGFβ predisposes HMECs to undergo TGFβ dependent EMT through activation of MAPK [34]. Furthermore, inhibition of MAPK with UO126 abrogated TGFβ-mediated EMT [34,35]. Interestingly, we observed reduced basal activation of MAPK in 231-GATA3 vs. 231-Empty cells. Therefore, the failure of TGFβ to promote EMT in 231-GATA3 cells could be due in part to the failure to reach a minimal threshold of activation of the MAPK pathway upon TGFβ stimulation. Although activation of Akt was also implicated in altering the response to TGFβ [32], C/EBPβ exists as 3 different isoforms, LAP1, LAP2 and LIP. LIP has a dominant negative effect on LAP1 and 2 that function as transcriptional regulators. Breast cancer cells with an elevated LIP:LAP ratio were shown to escape the TGFβ cytostatic response that correlates with a poorly differentiated phenotype and poor prognosis in breast cancer patients [32]. GATA3 was shown to interact with C/EBPβ and β in adipocytes and abrogate adipocyte differentiation [33]. Thus, GATA3 may also influence the TGFβ response in breast cancer cells by influencing the response through C/EBP transcription factors. Further studies will be needed to more precisely decipher potential novel mechanisms of GATA3 interactions with the TGFβ signaling pathways.

In addition to activating Smads, TGFβ treatment can also activate non-canonical pathways. TGFβ treatment of human mammary epithelial cells (HMECs) or normal murine mammary gland (NMUMG) cells activates MAPK [34,35]. In HMECs, TGFβ stimulation alone was not sufficient to promote EMT. Co-administration of ionizing radiation with TGFβ predisposes HMECs to undergo TGFβ dependent EMT through activation of MAPK [34]. Furthermore, inhibition of MAPK with UO126 abrogated TGFβ-mediated EMT [34,35]. Interestingly, we observed reduced basal activation of MAPK in 231-GATA3 vs. 231-Empty cells. Therefore, the failure of TGFβ to promote EMT in 231-GATA3 cells could be due in part to the failure to reach a minimal threshold of activation of the MAPK pathway upon TGFβ stimulation. Although activation of Akt was also implicated in the TGFβ-mediated EMT response in NMUMG cells [36], 231-GATA3 cells did not show changes in Akt phosphorylation compared to 231-Empty cells (data not shown).

Although, the role of TGFβ signaling in cancer and EMT has been extensively studied, there is increasing evidence that other members of the TGFβ superfamily, BMPs, also play an important role in cancer progression. Activation of BMP signaling results in phosphorylation of Smad1/5/8 which competes with Smad2/3 for binding to the co-Smad4. BMP7 decreased cell growth in HCC1954, MDA-MB-361, T-47D and ZR-75-30 cells [37]. BMP9 and BMP2 inhibited proliferation in MB-231 cells [38,39]. BMP7 treatment reduced tumorigenesis in MB-231 xenografts [40] and reversed the TGFβ-induced EMT in renal tubular epithelial cells [41]. BMP5 can reduce proliferation in xenografts [40] and reversed the TGFβ-induced EMT in renal tubular epithelial cells [41].

Figure 7. GATA3 upregulates BMP5 in MB-231 cells. (A) Q-RT-PCR showing expression of BMP2, BMP4 and BMP5 in 231-Empty and 231-GATA3 cells. GATA3 significantly upregulates BMP5 expression in MB-231 cells. (B) Western Blot analysis showing increased pSMAD1/5/8 in TGFβ1 or BMP5 treated 231-GATA3 cells compared to 231-Empty cells. β-actin was used as a loading control. (C) BrdU incorporation in pulse-labeled 231-Empty and 231-GATA3 cells as measured by flow cytometry. Bar graph shows % cells in S phase (mean +/- SEM).

doi:10.1371/journal.pone.0061125.g007

acquisition of an EMT phenotype has been associated with the acquisition of stem cell phenotype [11]. Further studies will decipher the interplay existing between these major pathways.

One potential mechanism utilized by GATA3 to promote all these changes is through epigenetic changes. We observed a reduction in methylation at the E-cadherin promoter and by methylation array we previously observed global changes in methylation (data not shown). Therefore, it is plausible that the epigenetic modifications promoted by GATA3 may result in the hypermethylation of transcription factors or genes associated with EMT.

Several mechanisms have been proposed to describe the paradoxical role of the TGFβ proliferative response. One known mechanism is through modulation of disabled homolog 2 (DAB2). DAB2 is an adaptor protein that regulates clathrin-mediated endocytosis [31]. Small cell carcinoma (SCC) cell lines expressing elevated levels of DAB2 remain sensitive to the anti-proliferative effects of TGFβ. In contrast, cells with reduced expression of DAB2 continue to proliferate upon TGFβ stimulation [31]. Furthermore, cells become resistant to the TGFβ cytostatic response upon DAB2 knock down [31]. In addition to DAB2, the transcription factor C/EBPβa member of the basic leucine zipper family of transcription factors, has been implicated in altering the response to TGFβ [32]. C/EBPβ exists as a different isoforms, LAP1, LAP2 and LIP. LIP has a dominant negative effect on LAP1 and 2 that function as transcriptional regulators. Breast cancer cells with an elevated LIP:LAP ratio were shown to escape the TGFβ cytostatic response that correlates with a poorly differentiated phenotype and poor prognosis in breast cancer patients [32]. GATA3 was shown to interact with C/EBPβ and β in adipocytes and abrogate adipocyte differentiation [33]. Therefore, GATA3 may also influence the TGFβ response in breast cancer cells by influencing the response through C/EBP transcription factors. Further studies will be needed to more precisely decipher potential novel mechanisms of GATA3 interactions with the TGFβ signaling pathways.

GATA3 Induced Growth Inhibition by TGFβ
PANC-1 cells [42] but the role of BMP5 in breast cancer is unknown.

The crosstalk between TGFβ and BMP5 is beginning to be deciphered. BMP5 has been shown to reverse the TGFβ-induced EMT and cell transformation of human kidney cells with a significant downregulation in α-smooth muscle actin expression and a significant increase of ZO-1, a marker of MET [43]. More recently, the repression of BMP5 levels by TGFβ1 has been directly implicated in the induction of EMT, with BMP5 acting as a suppressor of TGFβ-mediated Snail expression and downregulation of E-cadherin [44]. These reports are in accordance with our observations of increased E-cadherin and ZO-1 levels and reduced Snail-1 levels in 231 cells overexpressing GATA-3. The significant upregulation of BMP5 in 231-GATA3 cells may dampen the response of 231 cells to TGFβ by enforcing a more epithelial phenotype through the expression of epithelial markers and reducing the expression of EMT markers.

Here we have shown for the first time that although BMP5 or TGFβ alone has little effect on proliferation in MB-231 cells, combined treatment of BMP5 with TGFβ has a cytostatic effect on MB-231 cells. Additionally, we demonstrated that the inhibitory effect of TGFβ on the proliferation of MIII cells is suppressed if GATA3 or BMP are knocked-down by siRNA, further demonstrating an interaction between these genes and the TGFβ signaling pathway. This suggests a potential additional mechanism contributing to the switch in the TGFβ response.

An interplay between GATA3 and TGFβ is also evident during T cell differentiation. Both TGFβ and GATA3 play important roles in modulating the T Helper (Th) lineage. GATA3 drives Th cells into Th2 differentiation and suppresses Th1 specification [1]. GATA3 directly activates expression of Th2 specific cytokines, IL-4, IL-5 and IL-13 and suppresses Th1 specific cytokines, IFN-γ and IL-12 [1]. In contrast, TGFβ inhibits Th2 development through inhibition of GATA3 expression [45]. Furthermore, GATA3 abrogates TGFβ dependent FOXP3 induction, a factor expressed in naı̂ve T cells resulting in the inhibition of the development of iTreg cells [46]. The results of this study demonstrate for the first time that an interplay between TGFβ signaling and GATA3 also exists in breast cancer. Further studies may unravel a potential direct link between GATA3 and TGFβ signaling during mammary gland development and luminal/basal differentiation.

Given the important role of GATA3 in subtype specification and the TGFβ dependent EMT phenotypic transition, it is plausible that GATA3 may also be critical in mediating responses to therapy. Breast cancer patients receiving the aromatase

Figure 8. GATA3 and BMP5 knock down in MIII mammary epithelial cells decrease growth suppressive effect of TGFβ. (A) Western blot analysis of GATA3 in MIII cells transfected with control or GATA-3 siRNA. (B) Flow cytometric analysis of MIII cells after transfection with control or GATA3 siRNA and TGFβ treatment. (C) Quantitative RT-PCR analysis of BMP5 expression after transfection with control or BMP5 siRNA. (D) Flow cytometric analysis of MIII cells after transfection with control or BMP5 siRNA and TGFβ treatment. More cells were in proliferative state (S-phase) after knockdown of GATA-3 (B) or BMP5 (D) and subsequent TGFβ treatment than control siRNA-transfected cells treated with TGFβ. All values were normalized to that of the TGFβ untreated cells.

doi:10.1371/journal.pone.0061125.g008
inhibitor, letrozole, showed enrichment in claudin-low patterns post-treatment compared to pretreated tumors. Further analysis of mesenchymal markers by immunohistochemistry and automated quantitative analysis (AQUA) revealed an enrichment of mesenchymal markers in 26 paired patient samples post-treatment [47]. These findings suggest that tumors that have undergone EMT or express a mesenchymal phenotype may be more resistant to current therapeutic approaches [47]. Since GATA3 is associated with a more epithelial and luminal subtype, an increased understanding of the mechanisms utilized by GATA3 to reverse EMT and TGFβ response and to promote a more luminal subtype may also lead to the identification of novel approaches to sensitize resistant breast cancers to therapies. Therefore, the 231-GATA3 and 231-Empty cell line model we have developed may not only serve to further elucidate the underlying mechanisms controlling the TGFβ proliferative response, but it may also serve as a good model to investigate therapeutic response in luminal vs. basal breast cancer cells.

Acknowledgments

We are grateful to Lalage Wakefield for useful discussions and advice regarding this work, the NCI Bioinformatics Core for assistance with microarray analyses and Barbara Taylor of the NCI Flow Cytometry Core for assistance with flow cytometry.

Author Contributions

Conceived and designed the experiments: IMC JEG OA LET. Performed the experiments: IMC WCL HKM OA LET. Analyzed the data: IMC WCL JEG. Contributed reagents/materials/analysis tools: IMC HKM. Wrote the paper: ICM JEG.

References

1. Zhou M, Ouyang W (2003) The function role of GATA-3 in Th1 and Th2 differentiation. Immunol Res 28: 25–37.
2. Krouse-Mehr H, Slorach EM, Sterndich MD, Werb Z (2006) GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127: 1041–1053.
3. Asuel-Lahat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, et al (2007) Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 9: 201–209.
4. Yoon NK, Marsh EL, Shen D, Eshbiami Y, Apple S, et al (2010) Higher levels of GATA3 predict better survival in women with breast cancer. Hum Pathol 41: 1794–1801.
5. Chu IM, Michaloski AM, Hoenerhoff M, Szafter KM, Laguer D, et al (2011) GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells. Oncogene 31(16): 207–212, 2012.
6. Yan W, Cao QJ, Arenas RB, Boney R, Shao R (2010) GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. J Biol Chem.
7. Dydenborg AB, Rose AA, Wilson BJ, Grode D, Paquet M, et al (2009) GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. Oncogene 28: 2634–2642.
8. Thiry JP, Adequo H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871–890.
9. Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition at the crossroads of development and tumor metastasis. Dev Cell 14: 818–829.
10. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420–1428.
11. Polley K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265–275.
12. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, et al (2008) Loss of E-cadherin restricts breast cancer cells. Nature 450: 223–227.
13. Micalizzi DS, Farabaugh SM, Ford HL, Dalgin G, Hotamisligil GS (2005) Interaction between BMP7 and estrogen primes breast cancer cells. Cancer Res 65: 8430–8437.
14. Zou M, Ouyang W (2003) The function role of GATA-3 in Th1 and Th2 differentiation. Immunol Res 28: 25–37.
43. Bramlage CP, Muller GA, Tampe B, Bevanda J, Maatouk I, et al (2011) The role of bone morphogenetic protein-5 (BMP-5) in human nephrosclerosis. J Nephrol 24: 647–655.

44. Romagnoli M, Belguise K, Yu Z, Wang X, Landesman-Bollag E, et al (2012) Epithelial-to-mesenchymal transition induced by TGF-beta1 is mediated by Blimp-1-dependent repression of BMP-5. Cancer Res 72: 6268–6278.

45. Gorelik L, Fields PE, Flavell RA (2000) Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol 165: 4773–4777.

46. Mantel PY, Kasperek H, Boyman O, Rhyner C, Ouaked N, et al (2007) GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells. PLoS Biol 5: e329.

47. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, et al (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 106: 13820–13825.